Abstract: The present application provides fusion proteins that comprise a cytokine fused to an albumin binding moiety. The fusion proteins may further comprise an antigen binding moiety such as a therapeutic antibody. The present application also provides methods of making and using the fusion proteins. The present application also provides methods of treatment comprises administering a fusion protein comprising a cytokine fused to a half-life extending domain and a second agent.

Abstract: A lift pin includes a lift pin body arranged along a lift pin axis having a contact pad, a stem segment, a neck segment, and a span feature. The contact pad is defined at a first end of the lift pin body, the stem segment extends from the contact pad, and the neck segment extends from the stem segment. The span feature is defined at a second end of the lift pin body, is connected to the contact pad by the neck segment and the stem segment, and has a minor and major widths. The minor width is equivalent to a neck diameter defined by the neck segment, the major with is greater than the minor width, and the major width is greater than a stem diameter defined by the stem segment. Lift pin arrangements, semiconductor processing systems, and methods of making semiconductor processing systems are also described.

Abstract: Provided herein are an IL-2 fusion protein and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

Abstract: Provided herein are fusion proteins comprising an ST2 domain or IL-33 domain or an ST2 domain, and a half-life-extension domain. Also provided herein are their pharmaceutical compositions and methods of use for treating, preventing, or ameliorating one or more symptoms of an IL-33-mediated disorder, disease, or condition.

Abstract: The present application relates to anti-mesothelin constructs (such as antimesothelin antibodies, cytokine fusion proteins that comprise the anti-mesothelin constructs), methods of preparing the anti-mesothelin constructs and methods of using the constructs (e.g., methods of treating a disease or condition). The present application also relates to a combination therapy for treating cancer that comprises administering anti-mesothelin agent and a cytokine (such as IL-21 or IL-15). Combination therapy may further comprises administration of an anti-Her2 agent.

Abstract: Provided herein are a fusion protein comprising an interleukin-2 domain, a programmed cell death-1 binding domain, and a half-life-extension domain; and a pharmaceutical composition thereof. Also provided herein is a method of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

Abstract: An object mapping system for determination of a point of interest (POI) in an environment, including: creating a map of the environment; performing object recognition to locate objects of interest based on characteristics of the environment; generating a map with tags of the objects and the characteristics; providing navigation to guide a device to an object of interest selected from the objects based on a distance from a current location to a destination location of the device; determining angles from an initial position of a laser pointer to the object; generating signals to rotate servomotors based on the angles; processing the signals to rotate the servomotors such that the pointer is rotated from the initial position in coordinate-based directional angles to the object; generating a laser beam that targets the object for determination of the POI associated with the object that is associated with destination location of the computing device.

Abstract: Provided herein are an interleukin-2 polypeptide and a fusion protein thereof. Also provided herein are their pharmaceutical compositions and methods of use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

Abstract: A method for producing photocatalytic mortar includes providing a mortar-producing material including a fine aggregate and cement, a reactant mixture including a zinc source and urea, and a microorganism-containing mixture including water and a urease-producing microorganism, subjecting the microorganism-containing mixture and the reactant mixture to microbial induced precipitation in the mortar-producing material, subjecting zinc carbonate crystal-containing mortar produced to curing for the same to undergo hydration, and subjecting cured mortar to hydrothermal synthesis, so that zinc carbonate crystals therein are converted to nano zinc oxide crystals.

Abstract: An electro-optic device is described. The electro-optic device includes at least one optical material having an electro-optic effect. Further, the optical material(s) include lithium. The optical material(s) have a slab and a ridge waveguide. The slab has a top surface. The slab includes free surfaces. Each of the free surfaces is at a nonzero angle from the top surface of the slab and mitigates stress in the slab.

Abstract: Provided herein are a fusion protein comprising first and second cytokine domains, and a half-life extension domain; and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

Abstract: An optical device includes a substrate, an oxide layer on the substrate and an electro-optic device on the oxide layer. The oxide layer is at least one micrometer thick. The electro-optic device includes an electro-optic material having a thickness of not more than one micrometer. The silicon substrate, oxide layer, and the electro-optic material terminate at an edge. At least one of the silicon substrate has a thickness of at least five hundred micrometers or the edge includes a recessed region corresponding to a portion of the oxide layer.

Abstract: Provided herein are a fusion protein comprising first and second cytokine domains, and a half-life extension domain; and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

Abstract: A method for producing photocatalytic mortar includes providing a mortar-producing material including a fine aggregate and cement, a reactant mixture including a zinc source and urea, and a microorganism-containing mixture including water and a urease-producing microorganism, subjecting the microorganism-containing mixture and the reactant mixture to microbial induced precipitation in the mortar-producing material, subjecting zinc carbonate crystal-containing mortar produced to curing for the same to undergo hydration, and subjecting cured mortar to hydrothermal synthesis, so that zinc carbonate crystals therein are converted to nano zinc oxide crystals.

Abstract: A system associated with predicting authentication of a device user based on a joint features representation related to an echo-signature associated with a device is disclosed. The system performs operations that include emitting acoustic signals in response to a request for processing of a profile associated with the device. The system receives a set of echo acoustic signals that are tailored based on reflection of the acoustic signals from unique contours of one or more depth portions associated with the user relative to a discrete epoch. One or one or more region segments associated with the echo acoustic signals are extracted in order to train a classification model. A classification model is generated based on the one or more region segments as extracted. A joint features representation based on the classification model is generated. A vector-based classification model is used in the prediction of the joint features representation.

Abstract: The present disclosure provides anti-albumin constructs each comprising an antialbumin single-domain antibody (sdAb) moiety. The anti-albumin constructs can further comprise a therapeutic agent, such as an antigen binding moiety or a cytokine. The present disclosure also provides methods of making and using the anti-albumin constructs.

Abstract: Provided herein are a fusion protein comprising an interleukin-22 domain and an albumin binding domain, and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an inflammatory disease.

Abstract: Provided herein are an interleukin-2 polypeptide and a fusion protein thereof. Also provided herein are their pharmaceutical compositions and methods of use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

Abstract: The present application relates to anti-mesothelin constructs (such as antimesothelin antibodies, cytokine fusion proteins that comprise the anti-mesothelin constructs), methods of preparing the anti-mesothelin constructs and methods of using the constructs (e.g., methods of treating a disease or condition). The present application also relates to a combination therapy for treating cancer that comprises administering anti-mesothelin agent and a cytokine (such as IL-21 or IL-15). Combination therapy may further comprises administration of an anti-Her2 agent.

Abstract: The present application provides fusion proteins that comprise a cytokine fused to an albumin binding moiety. The fusion proteins may further comprise an antigen binding moiety such as a therapeutic antibody. The present application also provides methods of making and using the fusion proteins. The present application also provides methods of treatment comprises administering a fusion protein comprising a cytokine fused to a half-life extending domain and a second agent.